NCT00294931

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.

Detailed description

Eligible patients will receive 6 courses of irinotecan, carboplatin, and bevacizumab. The interval between chemotherapy courses will be 28 days. If after 6 courses of treatment, patient's response is a CR/PR/SD they will continue on Bevacizumab until tumor progression or up to 6 cycles (6 months) total. Treatment sequence: * Irinotecan 60mg/m2 on days 1, 8, and 15 * Carboplatin AUC=4 day 1 only * Bevacizumab 10 mg/kg days 1 and 15

Conditions

• Carcinoma, Small Cell Lung

Interventions

Type	Name	Description
DRUG	irinotecan
DRUG	carboplatin
DRUG	bevacizumab

Timeline

• Start date: 2006-02-01
• Primary completion: 2007-05-01
• Completion: 2009-01-01
• First posted: 2006-02-22
• Last updated: 2010-06-28

Locations

4 sites across 1 country: United States